Cite
HARVARD Citation
Nastoupil, L. et al. (2019). Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial. Lancet. 6 (2), pp. e100-e109. [Online].